Combination Treatment in Autoimmune Diseases

by W.B.Harrison (Editor), B . A . C . Dijkmans (Editor)

• New

  Hardcover
  2002

  $185.52

  Despite the advance of instituting monotherapy with a single optimised disease-modifying anti-rheumatic drug (DMARD) - with methotrexate as prototype agent in RA - adequate disease re- mission is not often achieved, and adverse events may well prevent the use of higher dosages of the single agent in question.